BUZZ-Eli Lilly falls on early data for rival Novo's amycretin obesity drug

Shares of U.S. drugmaker Eli Lilly LLY.N down 1.4% at $755.55 premarket

Danish rival Novo Nordisk NOVOb.CO said its next-generation obesity shot helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results

U.S.-listed shares of Novo rose nearly 12% premarket

Novo's experimental amycretin injection mimics the gut hormone GLP-1, but also mimics the effect of a hunger-suppressing pancreatic hormone called amylin

Novo's weight-loss treatment Wegovy competes directly with Lilly's Zepbound for market share

In a head-to-head study, Lilly's Zepbound was shown to be the more effective obesity drug

LLY stock has gained ~22% in the last 12 months